(Adnkronos) - “Abbiamo ad oggi un solo farmaco che modifica la malattia ma la ricerca sta andando avanti e, probabilmente, nei prossimi due-tre anni la potremo avere anche in commercio dei farmaci che modificano il decorso della malattia, senza trattare esclusivamente il sintomo”. Lo dichiara Angelo Labate, professore ordinario di Neurologia università di Messina, in occasione del 54° Congresso Sin - Società italiana di neurologia, in svolgimento a Roma fino al 12 novembre.
Category
🗞
NewsTranscript
00:00Epilepsy treatment lives in a traditional empirical phase with anti-crisis drugs, which are symptomatic drugs for both acute and symptomatic epileptic crises.
00:16That is, the patient who, perhaps for a stroke, comes to the emergency room for those who have sub-entering epileptic crises.
00:24And so we have the drugs that, fortunately, manage to stop the cluster of crises.
00:31And in addition we have the drugs that act instead on epilepsy syndromes and therefore on the genesis of epilepsy.
00:39Here, in this sense, research is moving forward.
00:41To date, we have only one drug that modifies the disease.
00:45In the case of tuberous sclerosis, it is an epileptogenic encephalopathy.
00:50But research is moving forward.
00:53Even if we have drugs that are specific for some epileptic syndromes,
00:58I can think of Travert's syndrome or Lennox-Gastaut's syndrome,
01:02always in epileptogenic encephalopathies,
01:07even if they do not modify the course of the disease.
01:10But probably in the next 2-3 years, research is taking giant steps.
01:16And we could also have on the market drugs that, perhaps, modify the course of the disease
01:22without treating the symptom exclusively.